

1 **Supplemental Methods**

2 **Inducible NASH model using wildtype mice**

3 Eight-week-old wildtype mice were kept under standard diet (SD) for 4 weeks, or fed Western  
4 diet (WD) for 16 weeks, and were received a single injection of CCl<sub>4</sub> (WAKO, Osaka, Japan)  
5 intraperitoneally at a dose of 0.1 ml/kg diluted 1:40 in olive oil. Then, the mice were kept on  
6 SD or WD and were sacrificed at each time point.

7 **Induction of hepatocyte death with anti-Fas antibody**

8 After 4-week WD feeding, MC4R-KO mice received a single injection of anti-Fas antibody  
9 (Jo2, BD Bioscience, San Jose, CA) intravenously at a dose of 10 µg/kg. Then, the mice were  
10 kept on WD and were sacrificed at each time point.

11

12

1 **Supplemental Table 1. Body and tissue weights in MC4R-KO mice reconstituted with**  
 2 **bone marrow cells from CCR2-KO mice.**

	WT/SD	MC4R/WD	
	WT-BM	WT-BM	CCR2 KO-BM
5 Body weight (g)	25.8 ± 0.3	46.8 ± 0.6**	44.0 ± 0.5
6 Liver (g)	1.28 ± 0.03	4.73 ± 0.28**	3.90 ± 0.22
7 Epididymal fat (g)	0.33 ± 0.01	1.45 ± 0.12**	1.65 ± 0.09
8 Blood glucose (mg/dl, <i>ad lib</i> )	129.6 ± 0.2	170.8 ± 6.9**	163.1 ± 14.0

9 WT, wildtype mice; MC4R, melanocortin 4 receptor-deficient mice; CCR2-KO, C-C  
 10 chemokine receptor 2-deficient mice; SD, standard diet; WD, Western diet; BM, bone marrow.

11 Data represent mean ± SEM. \*\* $P < 0.01$  versus WT-BM WT/SD (Tukey-Kramer test).  $n = 5-9$ .

12

1 **Supplemental Table 2. Primers used in this study**

2	Genes	Primers
3	<i>Ccr2</i>	Fw: ACAAATCAAAGGAAATGGAAGACAAT
4		Rv: TGCCGTGGATGAACTGAGG
5	<i>Clec4f</i>	Fw: GATGGGACACCATTCAACAATG
6		Rv: CTCTCCGTTCCCTATGTCTCCAGTT
7	<i>Coll1a1</i>	Fw: CCTCAGGGTATTGCTGGACAAC
8		Rv: ACCACTTGATCCAGAAGGACCTT
9	<i>Emr1</i>	Fw: CTTTGGCTATGGGCTTCCAGT
10		Rv: GCAAGGAGGACAGAGTTTATCGTG
11	<i>Itgam</i>	Fw: TTACCTGGGTTATGCTTCTGCAG
12		Rv: AAGCTTTGGACACGGTTCCTC
13	<i>Itgax</i>	Fw: GCCATTGAGGGCACAGAGA
14		Rv: GAAGCCCTCCTGGGACATCT
15	<i>Ly6c1</i>	Fw: GCAGTGCTACGAGTGCTATGG
16		Rv: ACTGACGGGTCTTTAGTTTCCTT
17	<i>Siglecl1</i>	Fw: GCAGCCTCTTTCAATGCTAAGG
18		Rv: TGTATTTGACGGTGTGATGACCA
19	<i>Tgfb1</i>	Fw: CCTGAGTGGCTGTCTTTTGACG
20		Rv: AGTGAGCGCTGAATCGAAAGC
21	<i>Timp1</i>	Fw: CATCACGGGCCGCCTA
22		Rv: AAGCTGCAGGCACTGATGTG
23	<i>Tnfa</i>	Fw: ACCCTCACACTCAGATCATCTTC
24		Rv: TGGTGGTTTGCTACGACGT
25	<i>18S</i>	Fw: GTAACCCGTTGAACCCCAT


1 Rv: CCATCCAATCGGTAGTAGCG

2 *36B4* Fw: GGCCCTGCACTCTCGCTTTC

3 Rv: TGCCAGGACGCGCTTGT

---


4



1  
2  
3  
4 **Supplemental Figure 1. Effect of CCR2 deficiency on inflammatory changes in the**  
5 **adipose tissue.**  
6 (A) F4/80 immunostaining in the epididymal fat from wildtype mice on standard diet (SD) and  
7 MC4R-KO mice reconstituted with CCR2-KO or wildtype mice-derived bone marrow cells on  
8 Western diet (WD) for 20 weeks. Scale bars, 50  $\mu$ m. (B) The number of F4/80-positive cells  
9 and crown-like structure (CLS). (C) The insulin tolerance test at 11 weeks of WD feeding.  
10 MC4R-KO mice were challenged with 1 U/kg insulin after 1 hour fasting, and blood glucose  
11 was measured at indicated time point. Data represent mean  $\pm$  SEM. \*\*  $P < 0.01$   
12 (Tukey-Kramer test).  $n = 5-9$ .

13

1




2  
3 **Supplemental Figure 2. Histological analysis and lipid content of the livers from bone**  
4 **marrow-specific CCR2-deficient MC4R-KO mice.**

5 Histological scores for hepatic steatosis, lobular inflammation, ballooning degeneration,  
6 NAFLD activity score (NAS) (A), and fibrosis stage (B). (C) Hepatic content of triglyceride  
7 and total cholesterol. (D) Representative images of immunostaining for αSMA. CV, central  
8 veins. Scale bars, 50 μm. Data represent mean ± SEM. \*\*  $P < 0.01$  (Tukey-Kramer test); n.s.,  
9 not significant.  $n = 5-9$ .

10


11




**Supplemental Figure 3. Dose-dependent effect of CCl<sub>4</sub> on hCLS formation and liver fibrosis.**

(A) Serum alanin aminotransferase (ALT) concentrations 1 day after CCl<sub>4</sub> injection. (B) hCLS number evaluated by F4/80 immunostaining. (C) Fibrosis area evaluated by Sirius red staining 7 days after CCl<sub>4</sub> injection. Data represent mean  $\pm$  SEM. \*  $P < 0.05$ , \*\*  $P < 0.01$  vs. veh (day 7) (2-tailed unpaired Student's  $t$  test).  $n = 5$ .


1  
2  
3  
4  
5  
6  
7  
8  
9  
10



1  
2  
3 **Supplemental Figure 4. Effect of low-dose CCl<sub>4</sub> on wildtype mice fed standard diet.**  
4 (A) Experimental protocol of CCl<sub>4</sub> injection to wildtype mice fed SD. Eight-week-old wildtype  
5 mice were kept under SD for 4 weeks, and received a single injection of CCl<sub>4</sub> at a dose of  
6 0.1ml/kg or olive oil as vehicle (Veh) intraperitoneally. (B) Time course of serum ALT  
7 concentrations after CCl<sub>4</sub> administration. Data represent mean ± SEM. \*\*  $P < 0.01$  vs. veh (day  
8 7); ##  $P < 0.01$  (Tukey-Kramer test). Representative images of F4/80 immunostaining (C) and  
9 Sirius red staining (D). Arrows, swollen hepatocytes. CV, central veins; PV, portal veins. Scale  
10 bars, 50 μm.  $n = 5-6$ .  
11  
12




1  
2  
3 **Supplemental Figure 5. Effect of low-dose CCl<sub>4</sub> on wildtype mice fed Western diet.**  
4 (A) Experimental protocol of CCl<sub>4</sub> injection to wildtype mice fed WD. Eight-week-old  
5 wildtype mice were fed WD for 16 weeks, and received a single injection of CCl<sub>4</sub> at a dose of  
6 0.1ml/kg or olive oil as vehicle (Veh) intraperitoneally. (B) F4/80 immunostaining, and (C)  
7 Sirius red staining 7 days after CCl<sub>4</sub> injection. Arrows, hCLS. CV, central veins. Scale bars, 50  
8 μm. Data represent mean ± SEM. \*  $P < 0.05$ , \*\*  $P < 0.01$  (2-tailed unpaired Student's  $t$  test).  $n$   
9 = 7-8.  
10



### Supplemental Figure 6. Anti-Fas antibody-induced hepatocyte death and hCLS formation.


(A) Experimental protocol for induction of hepatocyte death by anti-Fas antibody. Eight-week-old MC4R-KO mice were fed WD for 4 weeks, and received injection of anti-Fas antibody at a dose of 10 µg /kg (Fas) or normal saline (Veh) intravenously.  $n=5$ . (B) Changes in serum ALT levels 7 days after antibody injection. (C) TUNEL staining, (D) F4/80 immunostaining, and (E) Sirius red staining 7 days after antibody injection. Arrowheads, TUNEL-positive cells; Arrows, hCLS. Scale bars, 50 µm. (F) Hepatic mRNA expression of genes related to inflammation (*Emr1* (F4/80), *Tnfa*, and *Itgax* (CD11c)) and fibrogenesis (*Tgfb1* and *Colla1*). Data represent mean ± SEM. \*  $P < 0.05$ , \*\*  $P < 0.01$  (2-tailed unpaired Student's  $t$  test).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15




1  
2  
3 **Supplemental Figure 7. Role of CD11c-positive macrophages in hCLS formation in**  
4 **wildtype mice fed WD.**  
5 Representative images of immunofluorescent staining for Clec4f and CD169 (A), and F4/80  
6 and CD11c (B) of the livers from wildtype fed WD for 8 months. (C) Experimental protocol  
7 for depletion of CD11c-positive cells in CD11c-DTR bone marrow-chimeric wildtype  
8 (CD11c-DTR-BM WT) mice fed WD for 20 weeks. (D) Representative images of F4/80  
9 immunostaining and the number of hCLS. WT/SD, SD-fed WT-BM wildtype mice with DT  
10 treatment; Dep (-), WT-BM wildtype mice fed WD for 20 weeks with DT treatment; Dep (+),  
11 CD11c-DTR-BM wildtype mice fed WD for 20 weeks with DT treatment. Arrows, hCLS.  
12 scale bars, 50  $\mu$ m. N.D., not detected. \*\*  $P < 0.01$  (Tukey-Kramer test).  $n = 3-4$ .

13



1  
2  
3 **Supplemental Figure 8. Expression of CD11c in the restored macrophages after**  
4 **diphtheria toxin treatment in the conventional NASH model using MC4R-KO mice.**  
5 Representative images of immunofluorescent staining for F4/80 and CD11c of the livers from  
6 CD11c-DTR-BM MC4R-KO mice with or without macrophage depletion (4 and 10 days after  
7 DT treatment). Dep (-), WT-BM MC4R-KO mice fed WD for 20 weeks with DT treatment;  
8 Dep (+)\_day4 or 10, CD11c-DTR-BM MC4R-KO mice fed WD for 20 weeks at each time  
9 point after DT treatment. scale bars, 50  $\mu$ m.

10



1  
 2 **Supplemental Figure 9. Potential role of CD11c-positive resident macrophages in**  
 3 **hepatocyte death-triggered liver fibrosis in NASH.**  
 4 During the development of NASH, resident (CD169<sup>+</sup> F4/80<sup>hi</sup>) macrophages aggregate around  
 5 dying or dead hepatocytes to constitute hCLS, where CD11c-positive resident macrophages  
 6 promote liver fibrosis. Our data suggests that these macrophages in hCLS become  
 7 CD11c-positive in response to hepatocyte death, with unique polarization profiles. Therefore,  
 8 CD11c-positive resident macrophages in hCLS would be a novel macrophage subset that  
 9 drives hepatocyte death-induced liver fibrosis.  
 10